
CLAIMS

What is claimed is:

1. Use of Compound 67A represented by the following structural formula or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pancreatic cancer in a subject in need thereof:



(Compound 67A);

wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 250 mg/day to 500 mg/day.

2. The use of claim 1, wherein the subject is a human.

3. The use of claim 1 or 2, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 300 mg/day to 500 mg/day.

4. The use of claim 1 or 2, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 400 mg/day to 500 mg/day.

5. The use of claim 1 or 2, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from the group consisting of 250 mg/day, 260 mg/day, 270 mg/day, 280 mg/day, 290 mg/day, 300 mg/day, 310 mg/day, 320 mg/day, 330 mg/day, 340 mg/day, 350 mg/day, 360 mg/day, 370 mg/day, 380 mg/day, 390 mg/day, 400 mg/day, 410 mg/day, 420 mg/day, 430 mg/day, 440 mg/day, 450 mg/day, 460 mg/day, 470 mg/day, 480 mg/day, 490 mg/day, and 500 mg/day.

6. The use of claim 1 or 2, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from

the group consisting of 300 mg/day, 310 mg/day, 320 mg/day, 330 mg/day, 340 mg/day, 350 mg/day, 360 mg/day, 370 mg/day, 380 mg/day, 390 mg/day, 400 mg/day, 410 mg/day, 420 mg/day, 430 mg/day, 440 mg/day, 450 mg/day, 460 mg/day, 470 mg/day, 480 mg/day, 490 mg/day, and 500 mg/day.

7. The use of claim 1 or 2, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from the group consisting of 400 mg/day, 410 mg/day, 420 mg/day, 430 mg/day, 440 mg/day, 450 mg/day, 460 mg/day, 470 mg/day, 480 mg/day, 490 mg/day, and 500 mg/day.

8. The use of claim 1 or 2, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage of 400 mg/day.

9. The use of any one of claims 1-8, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 180 mg/m^2 to 500 mg/m^2.

10. The use of any one of claims 1-9, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 180 mg/m^2 to 400 mg/m^2.

11. The use of any one of claims 1-9, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 240 mg/m^2 to 500 mg/m^2.

12. The use of any one of claims 1-11, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage ranging from 240 mg/m^2 to 400 mg/m^2.

13. The use of any one of claims 1-9, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from the group consisting of 180 mg/m^2, 200 mg/m^2, 220 mg/m^2, 240 mg/m^2, 260

mg/m^2, 280 mg/m^2, 300 mg/m^2, 320 mg/m^2, 340 mg/m^2, 360 mg/m^2, 380 mg/m^2, 400 mg/m^2, 420 mg/m^2, 440 mg/m^2, 460 mg/m^2, 480 mg/m^2, and 500 mg/m^2.

14. The use of any one of claims 1-9, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from the group consisting of 240 mg/m^2, 260 mg/m^2, 280 mg/m^2, 300 mg/m^2, 320 mg/m^2, 340 mg/m^2, 360 mg/m^2, 380 mg/m^2, 400 mg/m^2, 420 mg/m^2, 440 mg/m^2, 460 mg/m^2, 480 mg/m^2, and 500 mg/m^2.

15. The use of any one of claims 1-12, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from the group consisting of 240 mg/m^2, 260 mg/m^2, 280 mg/m^2, 300 mg/m^2, 320 mg/m^2, 340 mg/m^2, 360 mg/m^2, 380 mg/m^2, and 400 mg/m^2.

16. The use of any one of claims 1-12, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at a dosage selected from the group consisting of 240 mg/m^2, 260 mg/m^2, 280 mg/m^2, 300 mg/m^2, 320 mg/m^2, 340 mg/m^2, and 360 mg/m^2.

17. The use of any one of claims 1-16, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, followed by a 14-day dosing holiday.

18. The use of any one of claims 1-16, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, followed by a 21-day dosing holiday.

19. The use of any one of claims 1-16, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at 240 mg/m^2 followed by a 14-day dosing holiday.

20. The use of any one of claims 1-16, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at 240 mg/m^2 followed by a 21-day dosing holiday.

21. The use of any one of claims 1-8, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at 120 mg/m^2 followed by a 14-day dosing holiday.

22. The use of any one of claims 1-8, wherein the medicament is formulated for administration of Compound 67A, or the pharmaceutically acceptable salt thereof, at 120 mg/m^2 followed by a 21-day dosing holiday.

23. The use of any one of claims 1-16, wherein the medicament is formulated for administration once daily.

24. The use of any one of claims 1-16, wherein the medicament is formulated for administration once every other day.

25. The use of any one of claims 1-16, wherein the medicament is formulated for adminstration once daily for four weeks.

26. The use of any one of claims 1-16, wherein the medicament is formulated for administration once daily for four weeks followed by a dosing holiday.

27. The use of any one of claims 1-26, wherein the medicament is a composition.